Evidence map›Paper›PMID 40828487›Full record

ArticleMedical oncology (Northwood, London, England)2025

Anticancer efficacy of nerolidol, cyclophosphamide, and their combination against breast cancer cell line MCF-7.

Md Tousif, Masood Nadeem, Ms Tabassum, M Moshahid Alam Rizvi, Syed Ehtaishamul Haque

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Md TousifDepartment of Pharmacology, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110025, India.
Masood NadeemGenome Biology Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India.
Ms TabassumDepartment of Pharmacology, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110025, India.
M Moshahid Alam RizviGenome Biology Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India.
Syed Ehtaishamul HaqueDepartment of Pharmacology, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110025, India. sehaq@jamiahamdard.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In cancer, chemotherapeutic agents like cyclophosphamide (CP), is the most frequently used drug but the side effects caused by it, limits it's application. Therefore, creation of anticancer medicines with high efficacy and no or minimum side effects is a priority. In recent times, research on natural bioactive has been increased since they are efficient, safe, and economical. We earlier proved that Nerolidol (NER), a naturally derived sesquiterpene alcohol is a natural bioactive compound that could significantly reduce the CP-induced organ toxicities in Swiss albino mice. Thus, in this study, we intended to evaluate the anti-cancer property of NER alone and its potentiating effect in combination with CP in Michigan Cancer Foundation-7 (MCF-7) breast cancer cell line. MCF-7 is one of the most extensively used human breast cancer cell line, primarily because it closely resembles estrogen receptor-positive (ER

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideSesquiterpenesApoptosisCell ProliferationDrug SynergismFemaleHumansMCF-7 CellsCyclophosphamidenerolidolSesquiterpenesBreast cancerCyclophosphamide (CP)Fetal Bovine Serum (FBS)MCF-7Nerolidol (NER)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.